Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07237100 · ClinicalTrials.gov registry record · Phase 2
Mirdametinib in Patients With Advanced NF1-mutant Melanoma
A Phase 2 study of Metastatic Melanoma and Advanced Unresectable Melanoma, sponsored by Kevin Kim, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT07237100: Recruiting Phase 2 study of Metastatic Melanoma and Advanced Unresectable Melanoma, sponsored by Kevin Kim, MD.
NCT07237100 is a Phase 2 study of Metastatic Melanoma and Advanced Unresectable Melanoma that is actively recruiting participants, run by Kevin Kim, MD. The registered enrollment target is 10 participants, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07237100, a Phase 2 study of Metastatic Melanoma and Advanced Unresectable Melanoma, is actively recruiting participants, sponsored by Kevin Kim, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to evaluate clinical efficacy of mirdametinib in patients with advanced NF1-mutant melanoma whose disease has progressed while on or after previous immunotherapy. The main questions this study aims to answer are: * To evaluate the feasibility of conducting a prospective single-center clinical trial of mirdametinib in patients with advanced NF1-mutant melanoma whose disease progresses during or after PD-1 antibody-based checkpoint inhibitor therapy. * To evaluate preliminary clinical efficacy of mirdametinib in patients with advanced NF1-mutant melanoma whose disease has progressed while on or after previous immunotherapy * To evaluate the safety profile of mirdametinib in patients with advanced NF1-mutant melanoma
Primary Outcome
This is a small pilot study to evaluate a feasibility of conducting a prospective single-center clinical trial of mirdametinib in patients with advanced NF1-mutant melanoma whose disease progresses during or after PD-1 antibody-based checkpoint inhibitor therapy. The primary endpoint is to enroll and treat 10 patients over a 12 month period. If there are at least 2 clinical responses among the 10 patients, the preliminary efficacy will be considered promising. Further discussions with the fundin
Conditions Studied
Interventions
- DRUG Mirdametinib
Study Locations (1)
California
- California Pacific Medical Center - Sutter Health - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-10-13 |
| Est. Completion | 2030-10-13 |
| Phase | Phase 2 |
What NCT07237100 shows while recruiting
NCT07237100 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Metastatic Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Mirdametinib is the first listed.
NCT07237100 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07237100 about?
NCT07237100 is a clinical study titled "Mirdametinib in Patients With Advanced NF1-mutant Melanoma". The goal of this clinical trial is to evaluate clinical efficacy of mirdametinib in patients with advanced NF1-mutant melanoma whose disease has progressed while on or after previous immunotherapy. The main questions this study aims to answer are: * To evaluate the feasibility of conducting a prosp...
What is the current status of trial NCT07237100?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2025-10-13. Estimated completion is 2030-10-13.
What conditions does trial NCT07237100 study?
This clinical trial studies the following conditions: Metastatic Melanoma, Advanced Unresectable Melanoma.
What interventions are being tested in trial NCT07237100?
The interventions under investigation include: Mirdametinib (DRUG).
Who is sponsoring clinical trial NCT07237100?
This trial is sponsored by Kevin Kim, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07237100 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07237100's enrollment target sits among peer trials
10 88th of 91 higher than 3 of 91 other Metastatic Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
RECRUITING · Phase 2
-
Cryoablation+Ipilimumab+Nivolumab in Melanoma
RECRUITING · Phase 2
-
Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
RECRUITING · Phase 2
-
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
RECRUITING · Phase 2
-
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI